Skip to main content
Immunotech Biopharm Ltd logo

Immunotech Biopharm Ltd — Investor Relations & Filings

Ticker · 6978 ISIN · KYG4721A1004 HKEX Manufacturing
Open in API
Filings indexed 256 across all filing types
Latest filing 2023-11-24 Regulatory Filings
Country HK Hong Kong
Listing HKEX 6978

About Immunotech Biopharm Ltd

http://www.eaal.net

Immunotech Biopharm Ltd is a biopharmaceutical company specializing in the research, development, manufacturing, and commercialization of cellular immunotherapy products. The company focuses primarily on T cell immunotherapy, applying principles of immunology, cell biology, and genetics combined with advanced technology to develop treatments for malignant tumors and other major diseases. Founded in 2006, it is recognized as a pioneer in the domestic development of cellular immunotherapy products. It maintains a commitment to building systematic R&D platforms and GMP-compliant manufacturing facilities for individualized cell products.

Recent filings

Filing Released Lang Actions
VOLUNTARY ANNOUNCEMENT RECEIPT OF THE ACCEPTANCE NOTICE FOR THE INVESTIGATIONAL NEW DRUG APPLICATION FOR THE aT19 INJECTION
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement by Immunotech Biopharm Ltd regarding the receipt of an acceptance notice for an Investigational New Drug Application from a regulatory authority. It provides detailed information about the drug candidate, its background, and the company's business focus. There are no financial statements, earnings data, or management discussion of financial results. The document is an announcement of a regulatory milestone rather than a financial report or meeting material. It is not a report publication announcement since it contains substantive content about the drug and company. Therefore, the document fits best into the category of a general regulatory announcement or voluntary corporate announcement, which aligns with the Regulatory Filings (RNS) category as a fallback for miscellaneous announcements that do not fit other categories.
2023-11-24 English
VOLUNTARY ANNOUNCEMENT FIRST PATIENT ENROLLED IN THE PHASE I CLINICAL TRIAL FOR THE DENOCABTAGENE CILOLEUCEL INJECTION
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement by Immunotech Biopharm Ltd regarding the enrollment of the first patient in a Phase I clinical trial for a new drug candidate. It is an announcement of a clinical development milestone, not a financial report or regulatory filing. The text includes no financial statements, no voting results, no management changes, no audit information, and no detailed financial data. It is a corporate announcement about product development progress. The document length is 6280 characters, which is sufficient for a detailed announcement but does not contain financial or regulatory report content. Therefore, it fits best into the category of a general regulatory or corporate announcement that does not fit other specific categories, which is Regulatory Filings (RNS).
2023-11-07 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 October 2023
Regulatory Filings Classification · 95% confidence The document is a detailed monthly return report for movements in securities, specifically for Immunotech Biopharm Ltd, covering the month ended 31 October 2023. It includes information on authorized and issued share capital, share options, convertible bonds, and confirmations related to securities issuance. The document is submitted to the Hong Kong Exchanges and Clearing Limited and follows the format of a regulatory return under the Exchange Listing Rules. It is not a financial report like an annual or interim report, nor is it an earnings release or a management discussion. It is a regulatory filing providing detailed share capital and securities movement information as required by the exchange. Therefore, it fits best under the category of Regulatory Filings (RNS). The document length (9356 characters) and content confirm it is a substantive regulatory report rather than a brief announcement or certification.
2023-11-03 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2023
Regulatory Filings Classification · 95% confidence The document is a detailed monthly return regarding movements in securities for Immunotech Biopharm Ltd, including authorized share capital, issued shares, share options, convertibles, and confirmations related to securities issued. It is submitted to the Hong Kong Exchanges and Clearing Limited and references compliance with listing rules. The document is not a financial report, earnings release, or management discussion but rather a regulatory filing about share capital and securities movements. It is not a short announcement but a structured regulatory return. Therefore, it fits best under Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other specific categories.
2023-10-06 English
2023 INTERIM REPORT
Interim / Quarterly Report Classification · 100% confidence The document is titled '2023 INTERIM REPORT' and contains detailed financial and operational data highlights, corporate information, management discussion and analysis, and condensed consolidated financial statements. It covers a six-month period ended 30 June 2023, which is typical for an interim or quarterly report. The presence of unaudited financial data, management discussion, and condensed financial statements confirms it is a comprehensive financial report for a period shorter than a full fiscal year. Therefore, this document fits the definition of an Interim / Quarterly Report (IR). H1 2023
2023-09-21 English
VOLUNTARY ANNOUNCEMENT EAL WAS GRANTED BREAKTHROUGH THERAPY DESIGNATION FOR TREATMENT OF LIVER CANCER BY THE CENTER FOR DRUG EVALUATION
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement by Immunotech Biopharm Ltd regarding the granting of breakthrough therapy designation by the Center for Drug Evaluation (CDE) for their product EAL[®] for liver cancer treatment. It discusses regulatory status, clinical trial progress, and future plans for marketing approval. The document is an announcement of a regulatory milestone and clinical development update, not a financial report, earnings release, or management discussion. It does not contain financial statements or detailed financial data. It is not a report publication announcement since it contains substantive information about the breakthrough therapy designation and clinical trial status. The content fits best under a general regulatory announcement category. Therefore, the most appropriate classification is Regulatory Filings (RNS).
2023-09-05 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.